A Phase 1/2 interventional study of Regadenoson in Myocardial Ischemia and Coronary Artery Disease, sponsored by GE Healthcare. Recruiting at 5 sites in 4 countries. Open to participants aged 4 Weeks to 18 Years. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by GE Healthcare · Phase 1/2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing regadenoson in Coronary Artery Disease — 1 open to participants now, 1 under way, none of them phase 3. regadenoson · Coronary Artery Disease.
Among the 23 studies testing regadenoson in Coronary Artery Disease, this one is the 11th largest by planned enrollment, is one of 2 that started in 2021, is the only one in phase 1/2, and was the 23rd registered.
4,865 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
Browse Coronary Artery Disease studies →1 of the 23 studies testing regadenoson in Coronary Artery Disease is open now, in 4 countries.
By country, each count listing its studies:
regadenoson: first FDA approval 2008 (LEXISCAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 4 Weeks to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 4 · Phase 4 7
First in 2003; this study’s year is marked. 2 started in 2021.
This study's planned enrollment of 54 is below the median of 123 across 3,012 interventional studies indexed under Coronary Artery Disease.
Median enrollment 50 across the 23 interventional studies. Of the 20 that completed or were terminated, 17 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
GE Healthcare is the lead sponsor of 176 studies on the registry; 21 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.
15 studies in Coronary Artery Disease by GE Healthcare: 2 open now, 2 under way, none of them phase 3. Of 12 finished, 4 (33%) have results posted.
Among the 15 studies in Coronary Artery Disease by GE Healthcare, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2021, is the only one in phase 1/2, and was the 14th registered.
GE Healthcare’s Coronary Artery Disease studies by the year they started, since 2005.
1 of the studies testing regadenoson in Coronary Artery Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04604782GE HealthcareA Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing regadenoson in Coronary Artery Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GE Healthcare’s 15 in Coronary Artery Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-centre, open-label, single-dose safety, tolerability and PK-pharmacodynamics (PD) study of the vasodilator regadenoson in 3 paediatric age groups for whom a pharmacologic stress perfusion CMR test is clinically indicated; adolescents aged 12 to \<18 years (Cohort A), children aged 2 to \<12 years (Cohort B), and infants aged 1 to \<24 months and who weigh at least 3 kg (Cohort C). Regadenoson will be used as the pharmacologic stress agent in this study with MPI serving as both surrogate pharmacodynamic marker of the agent (MPR, MBF) and a clinically evaluable examination for the patient
This is a multi-centre, open-label, single-dose safety, tolerability and PK-pharmacodynamics (PD) study of the vasodilator regadenoson in 3 paediatric age groups for whom a pharmacologic stress perfusion CMR test is clinically indicated; adolescents aged 12 to \<18 years (Cohort A), children aged 2 to \<12 years (Cohort B), and infants aged 1 to \<24 months and who weigh at least 3 kg (Cohort C). Regadenoson will be used as the pharmacologic stress agent in this study with MPI serving as both surrogate pharmacodynamic marker of the agent (MPR, MBF) and a clinically evaluable examination for the patient.
At least 54 paediatric patients will be enrolled at approximately 10 centres in Europe: at least 24 adolescents aged 12 to \<18 years (Cohort A), at least 18 children aged 2 to \<12 years (Cohort B), and at least 12 infants aged 1 to \<24 months (Cohort C). The study will be conducted in facilities appropriate for children, and by personnel knowledgeable and skilled in working with paediatric patients. Every attempt will be made to minimise the discomfort of the procedures to the patients. General anaesthesia/sedation with no oral-intake instructions may be used in accordance with age / disease specific requirements of the patient and as deemed necessary by the investigator per standard of care / local practice. In addition, adequate resuscitation equipment and personnel trained and certified in advanced life support must be readily available when regadenoson is administered. A Data Safety Monitoring Board (DSMB) will be in place, and will formally review all safety, efficacy, PK and PD information during the conduct of the study to ensure the safety of patients.
The study will be performed in a sequential manner across the 3 age groups, by decreasing age from adolescents (Cohort A) to children (Cohort B) and to infants (Cohort C). Dosing recommendations for the paediatric population are based on effective dose levels and PK data in adults. Based on a fixed dose of 400 µg regadenoson administered to adults with a mean body weight of 83.8 kg (body weight range: 42 to 161 kg), the effective mean weight-based dose was 4.8 µg/kg (range: 2.5 to 9.5 µg/kg). Within each age group, dosing will be extrapolated from PK-PD data obtained in adults and will be based on body weight-categories to provide approximately the same exposure as 400 µg in adults. The study will start with Cohort A (adolescents). Before the start of dosing in Cohort B, all safety, PK, and PD data obtained in Cohort A will be reviewed by the DSMB. Before the start of dosing in Cohort C, all safety, PK, and PD data obtained in Cohorts A and B will be reviewed by the DSMB.
4,865 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
This study's planned enrollment of 54 is below the median of 123 across 3,012 interventional studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →GE Healthcare is the lead sponsor of 176 studies on the registry; 21 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.
Compared within Coronary Artery Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myocardial Ischemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
* Male or female adolescent aged from 12 to \<18 years (Cohort A) or child aged from 2 to \<12 years (Cohort B) or infant aged from 1 to \<24 months (Cohort C).
Exclusion Criteria:
* Prior allergic reaction to Gd contrast agents and/or regadenoson or any component of its formulation, or to aminophylline or to its components (ethylenediamine and theophylline).
Out of acceptable range sitting or semi-recumbent resting BP or HR (beats per minute [bpm]) at screening as provided below:
For Cohort C: 70 to 160 bpm
Note: If the patient is currently receiving prescribed medications containing any of these ingredients, re-screening can only be considered if found acceptable based on the best medical judgement of the investigator and after discussion with the medical monitor. Otherwise, patients with a positive urine drug test will be considered a screen failure.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Regadenoson
Drug: Regadenoson
Drug: Regadenoson
Regadenoson (Rapiscan®): Single i.v. bolus dose in stress rest CMR
Also known as: Rapiscan
Occurrence of Adverse Events (AEs) following administration of Regadenoson
An overall summary of AEs, SAEs, and Regadenoson-emergent AEs will be presented, coded using the Medical Dictionary for Regulatory Activities (MedDRA) and summarized by system organ class and preferred term.
Time frame: 70 hours after Regadenoson administration
Changes in physical examinations following administration of Regadenoson
The number of patients with changes in physical examination status from normal at baseline to abnormal at each post-administration time point will be summarized.
Time frame: Baseline and 2 hours after Regadenoson administration
Changes in physical examinations following administration of Regadenoson
The percentage of patients with changes in physical examination status from normal at baseline to abnormal at each post-administration time point will be summarized.
Time frame: Baseline and 2 hours after Regadenoson administration
Changes in oxygen saturation following administration of Regadenoson
The occurrence of post-administration vital sign values outside the normal limits will be summarized.
Time frame: Baseline, 15 and 5 minutes before Regadenoson administration and 1, 3, 6, 10, 15, 30 minutes and 1, 2 hours after Regadenoson administration
Changes in blood pressure in mmHg following administration of Regadenoson
The occurrence of post-administration vital sign values outside the normal limits will be summarized.
Time frame: Baseline, 15 and 5 minutes before Regadenoson administration and 1, 3, 6, 10, 15, 30 minutes and 1, 2 hours after Regadenoson administration
Changes in heart rate as bpm following administration of Regadenoson
The occurrence of post-administration vital sign values outside the normal limits will be summarized.
Time frame: Baseline, 15 and 5 minutes before Regadenoson administration and 1, 3, 6, 10, 15, 30 minutes and 1, 2 hours after Regadenoson administration
Changes in body temperature (as degree C) following administration of Regadenoson
The occurrence of post-administration body temperature values outside the normal limits will be summarized by counts and percentages by age group and actual dose.
Time frame: Baseline and 2 hours after Regadenoson administration
Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of Regadenoson
Descriptive statistics will be used to describe the observed values and change from baseline for ECG intervals (RR, QT, QTcF\[Fridericia\])
Time frame: Baseline, 1 and 2 hours after Regadenoson administration
Changes in serum chemistry following administration of regadenoson
The occurrence of post-administration clinical laboratory values outside the normal limits will be summarized.
Time frame: Baseline and 2 hours after Regadenoson administration
Time changes of regadenoson blood concentrations (ng/mL) with a single, body-weight adjusted i.v. dose in 3 paediatric populations: adolescents 12 to <18 years,children 2 to <12 years, and infants 1 to <24 months, and who weigh at least 3kg.
Blood samples for PK assessment will be collected and processed for measurement of Regadenoson blood concentrations. Concentration-time profiles will be evaluated using compartmental methods and a population approach with mixed-effect modelling. A summary will be listed by patient and summarized by age group and actual dose at each time point.
Time frame: 1, 3, 5, 10, and 20 minutes and 1 and 2 hours post Regadenoson administration
Determine the correlation between regadenoson PK concentration (ng/mL) and changes in HR (bpm), including impact of patient factors.
The correlation between regadenoson PK concentration and change in HR at different time points will be evaluated using compartment methods and a population approach with mixed-effect modelling adjusted for patient factors.
Time frame: 1, 3, 5, 10, and 20 minutes and 1 and 2 hours post Regadenoson administration
Determine the associated myocardial hyperaemic response after administration of regadenoson using dynamic first-pass perfusion magnetic resonance imaging (MRI).
The Myocardial perfusion reserve (MPR) and Myocardial blood flow (MBF) values derived from the quantitative image analysis of the myocardial perfusion images will be listed per patient and summarized with descriptive statistics by age group and actual dose.
Time frame: 1 hour post Regadenoson administration.
Determine the associated myocardial hyperaemic response after administration of regadenoson using dynamic first-pass quantitative myocardial perfusion reserve (MPR) analysis.
The Myocardial perfusion reserve (MPR) and Myocardial blood flow (MBF) values derived from the quantitative image analysis of the myocardial perfusion images will be listed per patient and summarized with descriptive statistics by age group and actual dose.
Time frame: 1 hour post Regadenoson administration.
Not enrolling at this site.
Not enrolling at this site.
Started May 2021 (actual). Primary completion is estimated for Dec 2026, 67 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Regadenoson